南科大医学院
官方公众号
Guoan Chen, M.D., Ph.D., Associate Professor in the School of Medicine, Southern University of Science and Technology. Dr. Chen received his medical degree from Xi'an Jiaotong University in Xi’an, China in 1986 and finished his M.S. program in Pulmonary Medicine in Xi’an Jiaotong University in 1992. He received his Ph.D. in oncology from Peking Union Medical College in 1999. In 2000, he joined Professor David G. Beer’s Tumor Biology Laboratory as a Research Fellow and completed his post-doctoral training in tumor molecular biology at the University of Michigan and was promoted to the faculty as Research Investigator at the University of Michigan Medical School in 2004. He was promoted to Research Assistant Professor in 2010, and Associate Research Scientist in 2017. Dr. Chen’s research interests are focused within the fields of genomics, proteomics, and bioinformatics in lung cancer. He utilizes the state of the art molecular technologies and approaches, including gene expression microarray, SNP array, miRNA array and RNA deep sequencing, etc. to identify molecular changes for patient survival, the early diagnosis and the molecular mechanism in lung cancer progression. He currently worked on micro-RNAs, long non-coding RNAs, and circRNAs for lung cancer diagnosis and prognosis, as well as the functional, mechanistic and therapeutic application of these molecules in lung cancer. He has published over 80 SCI research articles, such as Nature Medicine, Nature Biotechnology, Cancer Cell, JNCI，J Clinical Investigation, Nature Communications, Cancer Research, Clinical Cancer Research, J Thoracic Oncology，Genome Research， Developmental Cell, PNAS, and has been cited more than 8800 times with h-index 41, i10-index 64 (Google Scholar).
Molecular biology of lung cancer
Functional genomics
Non-coding RNA
The mechanisms of tumor metastasis and drug resistance
9/1981-7/1986 B.S. in Medicine, Xi'an Medical University (Xi’an Jiaotong University), Xi'an, China.
9/1988-6/1992 M.S. in Pulmonary Medicine, Xi'an Medical University (Xi’an Jiaotong University), Xi'an, China. (Mentor: Dechang Yang, M.D.)
9/1996-6/1999 Ph.D. in Oncology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. (Mentor: Yan Sun, M.D.)
7/1986-6/1993 Resident physician, Internal Medicine of the Second Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China
7/1993-8/1996 Attending physician/Assistant Professor of Respiratory Department, The Second Hospital of Xi'an Jiaotong University, Xi'an, China.
6/1999-2/2000 Attending physician/Assistant professor, The Department of Respiratory, The Second Hospital of Xi’an Jiaotong University, Xi'an, China
2/2003-10/2004 Research Associate II, The Department of Surgery, University of Michigan, Ann Arbor, Michigan, U.S.A.
11/2004- 8/2010 Research Investigator, The Department of Surgery, University of Michigan, Ann Arbor, Michigan, U.S.A.
9/2010- 8/2017 Research Assistant Professor, The Department of Surgery, University of Michigan, Ann Arbor, Michigan, U.S.A.
9/2017 – 10/2018 Associate Research Scientist, The Department of Surgery, University of Michigan, Ann Arbor, Michigan, U.S.A.
10/2018 – present Associate Professor, School of Medicine, Southern University of Science
and Technology
1. Balbin OA, Malik R, Dhanasekaran SM, Prensner JR, Cao X, Wu YM, Robinson D, Wang R, Chen G, Beer DG, Nesvizhskii AI, Chinnaiyan AM. The landscape of antisense gene expression in human cancers. Genome Res. 2015 Jul;25(7):1068-79. PMID:26063736 (IF:10.101).
2. He Y, Wang L, Liu W, Zhong J, Bai S, Wang Z, Thomas DG, Lin J, Reddy RM, Ramnath N, Carrott PW, Lynch WR, Orringer MB, Chang AC, Beer DG, Chen G*. MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer. Sci Rep. 2015 Jun 19;5:11471. PMID: 26088427 (*通讯作者) (IF:4.122).
3. Goswami MT*, Chen G*, Chakravarthi BV, Pathi SS, Anand SK, Carskadon SL, Giordano TJ, Chinnaiyan AM, Thomas DG, Palanisamy N, Beer DG, Varambally S. Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. Oncotarget. 2015 Sep 15; 6(27):23445-61. PMID: 26140362 (* co-first authors) (IF:5.168).
4. Nadal E, Truini A, Nakata A, Lin J, Reddy RM, Chang AC, Ramnath N, Gotoh N, Beer DG, Chen G*. A Novel Serum 4-microRNA Signature for Lung Cancer Detection. Sci Rep. 2015 Jul 23; 5:12464. PMID: 26202143 (*通讯作者) (IF:4.122).
5. Zhao L, Feng D, Chen G, Taylor JM. A unified Bayesian semiparametric approach to assess discrimination ability in survival analysis. Biometrics. 2015 Dec 17. PMID: 26676324 (IF:1.524).
6. Wang L, He Y, Liu W, Bai S, Xiao L, Zhang J, Dhanasekaran SM, Wang Z, Kalyana-Sundaram S, Balbin OA, Shukla S, Lu Y, Lin J, Reddy RM, Carrott PW Jr, Lynch WR, Chang AC, Chinnaiyan AM, Beer DG, Zhang J, Chen G*. Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer. Oncotarget. 2016 Feb 5. PMID: 26862852 (*通讯作者) (IF:5.168).
7. Raghunathan R, Cease K, Troeschel S, Zhao L, Gross M, Chen G, Chopra V, Ramnath N. Impact of Staging with Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans with Stage I-III Non-Small Cell Lung Cancer. Am J Clin Oncol. 2016 Jun 17. PMID:27322696 (IF:3.424).
8. Shukla S, Evans JR, Malik R, Feng FY, Dhanasekaran SM, Cao X, Chen G, Beer DG, Jiang H, Chinnaiyan AM. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. J Natl Cancer Inst. 2016 Oct 5;109(1). doi: 10.1093/jnci/djw200. Print 2017 Jan.PMID:27707839 (IF:12.589).
9. Shiratsuchi H, Wang Z, Chen G, Ray P, Lin J, Zhang Z, Zhao L, Beer D, Ray D, Ramnath N. Oncogenic Potential of CYP24A1 in Lung Adenocarcinoma. J Thorac Oncol. 2017 Feb;12(2):269-280. doi: 10.1016/j.jtho.2016.10.010. Epub 2016 Oct 26. PMID:27793774 (IF:12.460).
10. Xu J, Zhou W, Yang F, Chen G, Li H, Zhao Y, Liu P, Li H, Tan M, Xiong X, Sun Y. The β-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor. Nat Commun. 2017 Jan 16;8:14002. PMID: 28090088 (IF:12.353).
11. Zhang J, Feng S, Su W, Bai S, Xiao L, Wang L, Thomas DG, Lin J, Reddy RM, Carrott PW, Lynch WR, Chang AC, Beer DG, Guo YM, Chen G*. Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer. Sci Rep. 2017 Feb 15;7:42819. PMID: 28198463 (*通讯作者) (IF:4.122).
12. Liu Y, Bu L, Li W, Wu W, Wang S, Diao X, Zhou J, Chen G, Yang S. Increased AAA-TOB3 correlates with lymph node metastasis and advanced stage of lung adenocarcinoma. Int J Biol Markers. 2017 Jun 15: PMID:28623644 (IF:1.449).
13. Feng S, Zhang J, Su W, Bai S, Xiao L, Chen X, Lin J, Reddy RM, Chang AC, Beer DG, Chen G*. Overexpression of LINC00152 correlates with poor patient survival and knockdown impairs cell proliferation in lung cancer. Sci Rep. 2017 Jun 7;7(1):2982. PMID: 28592840 (*通讯作者) (IF:4.122).
14. Chockley PJ, Chen J, Chen G, Beer DG, Standiford TJ, Keshamouni VG. Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. J Clin Invest. 2018 Jan 11. PMID: 29324443 (IF:13.251).
15. Su W, Feng S, Chen X, Yang X, Mao R, Guo C, Wang Z, Thomas DG, Lin J, Reddy RM, Orringer MB, Chang AC, Yang Z, Beer DG, Chen G*. Silencing of long non-coding RNA MIR22HG triggers cell survival/death signaling via oncogenes YBX1, MET, and p21 in lung cancer. Cancer Res. 2018 Apr 18. PMID: 29669758 (*通讯作者) (IF:9.130).
16. Guo NL, Dowlati A, Raese RA, Dong C, Chen G, Beer DG, Shaffer J, Singh S, Bokhary U, Liu L, Howington J, Hensing T, Qian Y. A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer. EBioMedicine. 2018 May 31. PMID: 29861409 (IF:6.680).
17. Raghunathan R, Cease K, Troeschel S, Zhao L, Gross M, Chen G, Chopra V, Ramnath N Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Managementand Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer. Am J Clin Oncol. 2018 May;41(5):513-518, PMID:27322696 (IF:3.424).
18. Heiden BT, Chen G, Hermann M, Brown RKJ, Orringer MB, Lin J, Chang AC, Carrott PW, Lynch WR, Zhao L, Beer DG, Reddy RM. 18F-FDG PET intensity correlates with a hypoxic gene signature and other oncogenic abnormalities in operable non-small cell lung cancer. PloS One. 2018 Jul 2;13(7): PMID: 29966011 (IF:2.766).
19. Yu H, Chen Z, Ballman KV, Watson MA, Govindan R, Lanc I, Beer DG, Bueno R, Chirieac LR, Chui MH, Chen G, Franklin WA, Gandara DR, Genova C, Brovsky KA, Joshi MM, Merrick DT, Richards WG, Rivard CJ, Harpole DH, Tsao MS, van Bokhoven A, Shepherd FA, Hirsch FR. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signature for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. J Thorac Oncol. 2019 Jan;14(1):25-36. PMID: 30253973 (IF:12.460).
20. Su W, Wang L, Niu F, Zou L, Guo C, Wang Z, Yang X, Wu J, Lu Y, Zhang J, Beer DG, Yang Z, Chen G*. LINC00857 knockdown inhibits cell proliferation and induces apoptosis via involving STAT3 and MET oncogenic proteins in esophageal adenocarcinoma. Aging (Albany NY). 2019 May 13;11(9):2812-2821. PMID: 31085800 (*通讯作者) (IF:5.515).
21. Cheng G, Zhang Q, Pan J, Lee Y, Ouari O, Hardy M, Zielonka M, Myers CR, Zielonka J, Weh K, Chang AC, Chen G, Kresty L, Kalyanaraman B, You M. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019 May 17;10(1):2205. PMID: 31101821 (IF:11.878).
22. Li L, Kang J, Zhang W, Cai L, Wang S, Liang Y, Jiang Y, Liu X, Zhang Y, Ruan H, Chen G, Wang M, Jia L.Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer. EBioMedicine. 2019 Jun 14. PMID: 31208947(IF:6.680)
23. Yang X, Zhang Q, Zhang M, Su W, Wang Z, Li Y, Zhang J, Beer DG, Yang S, Chen G*. Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer. Int J Biol Sci. 2019 Jun 10;15(8):1712-1722. doi: 10.7150/ijbs.33986. eCollection 2019. PMID: 31360113 (*通讯作者) (IF:4.06)
24. Chen X, Mao R, Su W, Yang X, Geng Q, Guo C, Wang Z, Wang J, Kresty LA, Beer DG, Chang AC, Chen G*. Circular RNA circHIPK3 modulates autophagy via MIR124-3p-STAT3-PRKAA/AMPKα signaling in STK11 mutant lung cancer. Autophagy. 2019 Jun 23. doi: 10.1080/15548627.2019.1634945. [Epub ahead of print] PMID: 31232177 (*通讯作者) (IF:11.059)
25. Su W, Guo C, Wang L, Wang Z, Yang X, Niu F, Tzou D, Yang X, Huang X, Wu J, Chen X, Zou L, Yang Z, Chen G. LncRNA MIR22HG abrogation inhibits proliferation and induces apoptosis in esophageal adenocarcinoma cells via activation of the STAT3/c-Myc/FAK signaling. Aging (Albany NY). 2019 Jul 10;11. doi: 10.18632/aging.102071. [Epub ahead of print] PMID: 31291201 (*通讯作者) (IF: 5.515).
26. Yin Y, Xie CM, Li H, Tan M, Chen G, Schiff R, Xiong X, Sun Y.The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells. Proc Natl Acad Sci U S A. 2019 Sep 23. pii: 201905973. doi: 10.1073/pnas.1905973116. [Epub ahead of print] PMID: 31548378 (IF:9.58)
27. Xia Yang, Wenmei Su, Xiuyuan Chen, Qianqian Geng, Jingyi Zhai, Hu Shan, Chunfang Guo, Zhuwen Wang, Han Fu, Hui Jiang, Jules Lin, Kiran Hari Lagisetty, Jie Zhang, Yali Li, Shuanying Yang, Pierre P Massion, David G. Beer, Andrew C. Chang, Nithya Ramnath, Guoan Chen*. Validation of A serum 4-microRNA signature for the detection of lung cancer. Translational Lung Cancer Research. 2019 Online (*通讯作者) (IF: 4.81).
28. Xia Yang, Qiuhong Zhang, Wenmei Su, Ming Zhang, Hu Shan, Jie Zhang, Guoan Chen, Chunfang Guo, Yali Li. Expression level of serum miRNA-22 and its clinical significance in patients with lung cancer. International Journal of Respiration. 2019 Sep, 39(18), 1373-1378
29. Jiang Y, Cheng W, Li L, Zhou L, Liang Y, Zhang W, Chen W, Wang S, Zhao H, Chen G, Zhou W, Ji G, Zhang Y, Hoffman RM, Wang M, Jia L. Effective targeting of the ubiquitin-like modifier NEDD8 for lung adenocarcinoma treatment. Cell Biol Toxicol. 2020 Jan 6. doi: 10.1007/s10565-019-09503-6. [Epub ahead of print] PMID: 31907687 (IF: 5.1).
30. Lyu X, Zeng L, Zhang H, Ke Y, Liu X, Zhao N, Yuan J, Chen G, Yang S. Hydroxychloroquine suppresses lung tumorigenesis via inducing FoxO3a nuclear translocation through STAT3 inactivation. Life Sci. 2020 Jan 27:117366. doi: 10.1016/j.lfs.2020.117366. [Epub ahead of print], PMID: 32001266 (IF: 3.5).
31. Huang W, Ray P, Ji W, Wang Z, Nancarrow D, Chen G, Galban S, Lawrence TS, Beer DG, Rehemtulla A, Ramnath N, Ray D. The cytochrome P450 enzyme CYP24A1 increases proliferation of mutant KRAS-dependent lung adenocarcinoma independently of its catalytic activity. J Biol Chem. 2020 Mar 12. pii: jbc.RA119.011869. doi: 10.1074/jbc.RA119.011869. [Epub ahead of print] PMID: 32165494 (IF: 4.13).
